{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:01:29Z","timestamp":1793314889532,"version":"4.5.0"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T00:00:00Z","timestamp":1483488000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s12016-016-8596-x","type":"journal-article","created":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T09:05:37Z","timestamp":1483520737000},"page":"40-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":209,"title":["Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review"],"prefix":"10.1007","volume":"53","author":[{"given":"Jaume","family":"Alijotas-Reig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Esteve-Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Ferrer-Oliveras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Llurba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Maria","family":"Gris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,4]]},"reference":[{"key":"8596_CR1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1600-0897.2010.00852.x","volume":"63","author":"S Saito","year":"2010","unstructured":"Saito S, Nakashima A, Shima T, Ito M (2010) Th1\/Th2\/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 63:601\u2013610","journal-title":"Am J Reprod Immunol"},{"key":"8596_CR2","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/893819","author":"MA Knippen","year":"2011","unstructured":"Knippen MA (2011) Michroquimerism: sharing genes in illness and in health. Intern Scholar Res Net. doi: 10.5402\/2011\/893819","journal-title":"Intern Scholar Res Net"},{"key":"8596_CR3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.contraception.2008.08.003","volume":"79","author":"J Trussell","year":"2009","unstructured":"Trussell J, Lalla A, Doan Q, Reyes E, Pinto L, Gricar J (2009) Cost effectiveness of contraceptives in the United States. Contraception 79:5\u201314","journal-title":"Contraception"},{"key":"8596_CR4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"CG Skorpen","year":"2016","unstructured":"Skorpen CG, Hoelzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75:795\u2013810","journal-title":"Ann Rheum Dis"},{"key":"8596_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev404","author":"J Flint","year":"2016","unstructured":"Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K et al (2016) BSR and BHPR guidelines on prescribing drugs in pregnancy and breastfeeding\u2014part I: standart and buiologic disease \u2013modifying anti-rheumatic drugs and corticosteroids. Rheumatology. doi: 10.1093\/rheumatology\/kev404","journal-title":"Rheumatology"},{"key":"8596_CR6","first-page":"1205","volume":"9","author":"M Majetschak","year":"2002","unstructured":"Majetschak M, Obertacke U, Schade FU, Bardenheuer M, Voggenreiter G, Bloemeke B et al (2002) Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients. Clin Diagn Lab Immunol 9:1205\u20131211","journal-title":"Clin Diagn Lab Immunol"},{"key":"8596_CR7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.cdd.4401189","volume":"10","author":"H Wajant","year":"2003","unstructured":"Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45\u201365","journal-title":"Cell Death Differ"},{"key":"8596_CR8","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1126\/science.1071924","volume":"296","author":"G Chen","year":"2002","unstructured":"Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296:1634\u20131635","journal-title":"Science"},{"key":"8596_CR9","first-page":"230742","volume":"2012","author":"J Brogin Moreli","year":"2012","unstructured":"Brogin Moreli J, Cirino Ruocco AM, Vernini JM, Rudge MV, Calderon IM (2012) Interleukin 10 and tumor necrosis factor-alpha in pregnancy: aspects of interest in clinical obstetrics. Obstet Gynecol 2012:230742","journal-title":"Obstet Gynecol"},{"key":"8596_CR10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/157339509788921238","volume":"5","author":"J Alijotas-Reig","year":"2009","unstructured":"Alijotas-Reig J (2009) Immunological puzzle related to recurrent miscarriage: overview. Curr Immunol Rev 5:175\u2013186","journal-title":"Curr Immunol Rev"},{"key":"8596_CR11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.placenta.2014.02.004","volume":"35","author":"J Alijotas-Reig","year":"2014","unstructured":"Alijotas-Reig J, Llurba E, Gris JM (2014) Potentiating maternal immune tolerance in pregnancy: a new challenging role for regulatory T cells. Placenta 35:241\u2013248","journal-title":"Placenta"},{"key":"8596_CR12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.2106","volume":"16","author":"EA Said","year":"2010","unstructured":"Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M et al (2010) Programmed death-1-induced interleukin-10 production by monocytes impairs CD4\u00a0+\u00a0T cell activation during HIV infection. Nature Med 16:452\u2013459","journal-title":"Nature Med"},{"key":"8596_CR13","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1093\/humrep\/14.9.2386","volume":"14","author":"S Quenby","year":"1999","unstructured":"Quenby S, Bates M, Doig T, Brewster J, Lewis-Jones DI, Johnson PM et al (1999) Pre-implantation endometrial leukocytes in women with recurrent miscarriage. Hum Reprod 14:2386\u20132391","journal-title":"Hum Reprod"},{"key":"8596_CR14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.fertnstert.2012.08.034","volume":"99","author":"P Banerjee","year":"2013","unstructured":"Banerjee P, Jana SK, Pasricha P, Ghosh S, Chakravarty B, Chaudhury K (2013) Proinflammatory cytokines induced altered expression of cylcooxigenase 2 gene results in unreceptive endometrium in women with idiopathic spontaneous miscarriage. Fertil Steril 99:179\u2013187","journal-title":"Fertil Steril"},{"key":"8596_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.05.011","author":"L Wedekind","year":"2016","unstructured":"Wedekind L, Belkacemi L (2016) Altered cytokine network in gestational diabetes mellitus affects maternal insulin and placental-fetal development. J Diabetes Complicat. doi: 10.1016\/j.jdiacomp.2016.05.011","journal-title":"J Diabetes Complicat"},{"key":"8596_CR16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1046\/j.1464-5491.2001.00614.x","volume":"18","author":"MT Coughlan","year":"2001","unstructured":"Coughlan MT, Oliva K, Georgion HM, Permezel JMH, Rice GE (2001) Glucose-induced release of tumour necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus. Diabet Med 18:921\u2013927","journal-title":"Diabet Med"},{"key":"8596_CR17","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2337\/diabetes.51.7.2207","volume":"51","author":"JP Kirwan","year":"2002","unstructured":"Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier JC, Huston-Presley L (2002) Friedman JE. Diabetes 51:2207\u20132213","journal-title":"Diabetes"},{"key":"8596_CR18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.diabres.2015.01.005","volume":"107","author":"JB Moreli","year":"2015","unstructured":"Moreli JB, Corr\u00eaa-Silva S, Damasceno DC, Sinzato YK, Lorenzon-Ojea AR, Borbely AU (2015) Changes in the TNF-alpha\/IL-10 ratio in hyperglycemia-associated pregnancies. Diabetes Res Clin Pract 107:362\u2013369","journal-title":"Diabetes Res Clin Pract"},{"key":"8596_CR19","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.4049\/jimmunol.174.1.485","volume":"174","author":"J Berman","year":"2005","unstructured":"Berman J, Girardi G, Salmon JE (2005) TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 174:1222\u20131226","journal-title":"J Immunol"},{"key":"8596_CR20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jri.2015.05.001","volume":"110","author":"J Yuan","year":"2015","unstructured":"Yuan J, Li J, Huang SY, Sun X (2015) Characterization of the subsets of human NKT-like cells and the expression of Th1\/Th2 cytokines in patients with unexplained recurrent spontaneous abortion. J Reprod Immunol 110:81\u201388","journal-title":"J Reprod Immunol"},{"key":"8596_CR21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0897.2006.00455.x","volume":"57","author":"JC Pera\u00e7oli","year":"2007","unstructured":"Pera\u00e7oli JC, Rudge MVC, Per\u00e7oli MTS (2007) Tumor necrosis factor-alpha in gestation and puerperium of women with gestational hypertension and pre-eclampsia. Am J Reprod Immunol 57:177\u2013185","journal-title":"Am J Reprod Immunol"},{"key":"8596_CR22","first-page":"1","volume-title":"Major problems in internal medicine","author":"DG James","year":"1985","unstructured":"James DG, Williams WJ (1985) Sarcoidosis and other granulomatous disorders. In: Smith LLH (ed) Major problems in internal medicine, vol 24. W.B. Saunders Co, Philadelphia, pp 1\u2013254"},{"key":"8596_CR23","first-page":"731","volume-title":"Textbook of rheumatology [4th edition]","author":"RI Rynes","year":"1993","unstructured":"Rynes RI (1993) Antimalarial drugs. In: Kelley WN, Harris ED, Ruddyn S, Sledge CB (eds) Textbook of rheumatology [4th edition]. W.B. Saunders, Philadelphia, pp 731\u2013742"},{"key":"8596_CR24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0961203312465782","volume":"22","author":"J Alijotas-Reig","year":"2013","unstructured":"Alijotas-Reig J (2013) Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 22:6\u201317","journal-title":"Lupus"},{"key":"8596_CR25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.autrev.2014.12.010","volume":"14","author":"J Alijotas-Reig","year":"2015","unstructured":"Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A, Tincani A, Lefkou E, Bertero MT et al (2015) The European registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 14:387\u2013395","journal-title":"Autoimmun Rev"},{"key":"8596_CR26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.autrev.2014.08.040","volume":"14","author":"A Mekinian","year":"2015","unstructured":"Mekinian A, Costedoat-Chalumeau N, Masseau A, Tincani A, De Caroli S, Alijotas-Reig J et al (2015) Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? Autoimmun Rev 14:23\u201329","journal-title":"Autoimmun Rev"},{"key":"8596_CR27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1160\/TH14-03-0191","volume":"112","author":"A Ruffatti","year":"2014","unstructured":"Ruffatti A, Salvan E, Del Ross T, Gerosa M, Andreoli L, Alijotas-Reig J et al (2014) Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost 112:727\u2013735 Erratum in: Thromb Haemost. 2014 Dec;112","journal-title":"Thromb Haemost"},{"key":"8596_CR28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1055\/s-0037-1613033","volume":"87","author":"RG Espinola","year":"2002","unstructured":"Espinola RG, Pierangeli SS, Gharavi AE, Harris EN (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholid antibodies. Thromb Haemost 87:518\u2013522","journal-title":"Thromb Haemost"},{"key":"8596_CR29","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1161\/01.CIR.96.12.4380","volume":"96","author":"MH Edwards","year":"1997","unstructured":"Edwards MH, Pierangeli SS, Liu X, Barker JH, Anderson G, Harris EN (1997) Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96:4380\u20134384","journal-title":"Circulation"},{"key":"8596_CR30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2362.2010.02443.x","volume":"41","author":"G Ruiz-Irastorza","year":"2011","unstructured":"Ruiz-Irastorza G, Khamashta MA (2011) Lupus and pregnancy: integrating clues from the bench and bedside. Eur J Clin Investig 41:672\u2013678","journal-title":"Eur J Clin Investig"},{"key":"8596_CR31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1191\/0961203306lu2299oa","volume":"15","author":"A Wozniacka","year":"2006","unstructured":"Wozniacka A, Lesiak A, Narbutt JM, McCauliffe DP, Sysa-Jedrzejowska A (2006) Chloroquine treatment influences proinflammatory cytokine level in systemic lupus erythematosus patients. Lupus 15:268\u2013275","journal-title":"Lupus"},{"key":"8596_CR32","first-page":"24","volume":"45","author":"CP Mangubat","year":"2001","unstructured":"Mangubat CP, Thaker PP, Cavalcante M (2001) Etanercept and immune treatment in multiple IVF failures. Am J Reprod Immunol 45:24","journal-title":"Am J Reprod Immunol"},{"key":"8596_CR33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4049\/jimmunol.154.9.4261","volume":"154","author":"G Chaouat","year":"1995","unstructured":"Chaouat G, Assal-Meliani A, Martal J, Raghupathy R, Elliott JF, Mosmann T et al (1995) IL-10 prevents naturally occurring fetal loss in the CBAxDBA\/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN-tau. J Immunol 154:426\u2013428","journal-title":"J Immunol"},{"key":"8596_CR34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1142\/S0192415X08005655","volume":"36","author":"XH Zhong","year":"2008","unstructured":"Zhong XH, Shi WY, Ma AT, Gong XC, Zhai XH, Zhang T et al (2008) Efects of Radix scutellariae and Rhizoma atractylodis on LPS-induced abortion and the uterine IL-10 contents in mice. Am J Chin Med 36:141\u2013148","journal-title":"Am J Chin Med"},{"key":"8596_CR35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/eurjhf\/hfn040","volume":"11","author":"SM Shaw","year":"2009","unstructured":"Shaw SM, Shah MKH, Williams SG, Fildes JE (2009) Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Heart Fail 11:113\u2013118","journal-title":"Eur J Heart Fail"},{"key":"8596_CR36","first-page":"CD007677","volume":"1","author":"D Lu","year":"2012","unstructured":"Lu D, Song H, Li Y, Shi G (2012) Pentoxifylline for endometriosis. Cochrane Database Syst Rev 1:CD007677","journal-title":"Cochrane Database Syst Rev"},{"key":"8596_CR37","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/humrep\/den167","volume":"23","author":"M Creus","year":"2008","unstructured":"Creus M, Fabregues F, Carmona F, del Pino M, Manau D, Balasch J (2008) Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial. Hum Reprod 23:1910\u20131916","journal-title":"Hum Reprod"},{"key":"8596_CR38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/107602960100700401","volume":"7","author":"RL Bick","year":"2001","unstructured":"Bick RL (2001) Antiphospholipid thrombosis syndromes. Clin Appl Thromb Hemost 7:241\u2013258","journal-title":"Clin Appl Thromb Hemost"},{"key":"8596_CR39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0015-0282(02)04579-X","volume":"79","author":"H Letur-Konirsch","year":"2003","unstructured":"Letur-Konirsch H, Delanian S (2003) Successful pregnancies after combined pentoxifylline-tocopherol treatment in women with prematureovarian failure who are resistant to hormobe replacement therapy. Fertil Steril 79:439\u2013441","journal-title":"Fertil Steril"},{"key":"8596_CR40","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003495-200565050-00006","volume":"65","author":"MT Nurmohamed","year":"2005","unstructured":"Nurmohamed MT, Dijkmans BA (2005) Efficacy, tolerability and cost effectiveness of diseases-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 65:661\u2013694","journal-title":"Drugs"},{"key":"8596_CR41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M, Brito-Zeron P, Mu\u00f1oz S, Soria N, Galiana D, Bertolaccini L et al (2007) Autoimmune diseases induced by TNF-targeted therapies. Medicine (Baltimore) 86:242\u2013251","journal-title":"Medicine (Baltimore)"},{"key":"8596_CR42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","volume":"50","author":"HT Idriss","year":"2000","unstructured":"Idriss HT, Naismith JH (2000) TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 50:184\u2013195","journal-title":"Microsc Res Tech"},{"key":"8596_CR43","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jmb.2008.11.053","volume":"385","author":"Y Mukai","year":"2009","unstructured":"Mukai Y, Shibata H, Nakamura T, Yoshioka Y, Abe Y, Nomura T et al (2009) Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J Mol Biol 385:1221\u20131229","journal-title":"J Mol Biol"},{"key":"8596_CR44","first-page":"e413","volume":"164","author":"F Conti","year":"2013","unstructured":"Conti F, Ceccarelli L, Massaro E, Cipriano M, Di Franco C, Alessandri FR et al (2013) Biological therapies in rheumatic diseases. Clin Ter 164:e413\u2013e428","journal-title":"Clin Ter"},{"key":"8596_CR45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/OGX.0b013e3181c97809","volume":"65","author":"J Alijotas-Reig","year":"2010","unstructured":"Alijotas-Reig J, Vilardell-Tarr\u00e9s M (2010) Is obstetric antiphospholipid syndrome a primary non-thrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies? Obstet Gynecol Surv 65:39\u201345","journal-title":"Obstet Gynecol Surv"},{"key":"8596_CR46","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","volume":"7","author":"PL Meroni","year":"2011","unstructured":"Meroni PL, Borghi MO, Raschi E et al (2011) Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7:330\u2013339","journal-title":"Nat Rev Rheumatol"},{"key":"8596_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2016.05.020","author":"J Alijotas-Reig","year":"2016","unstructured":"Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R (2016) Treating pregnant women with systemic rheumatic or autoimmune disease with immunosuppressive and biologic drugs. Med Clin (Barc). doi: 10.1016\/j.medcli.2016.05.020","journal-title":"Med Clin (Barc)"},{"key":"8596_CR48","first-page":"570","volume":"33","author":"C Papagoras","year":"2015","unstructured":"Papagoras C, Voulgari PV, Drosos AA (2015) Golimumab, the newest TNF-\u03b1 blocker, comes of age. Clin Exp Rheumatol 33:570\u2013577","journal-title":"Clin Exp Rheumatol"},{"key":"8596_CR49","doi-asserted-by":"publisher","first-page":"e00197","DOI":"10.1002\/prp2.197","volume":"4","author":"M Cetrone","year":"2016","unstructured":"Cetrone M, Parisi G, Tricarico D, Pierri CL, Bossis F, Punzi G, De Grassi A (2016) Molecular modeling of antibodies for the treatment of TNF \u03b1 -related immunological diseases. Pharmacol Res Perspect 4:e00197. doi: 10.1002\/prp2.197","journal-title":"Pharmacol Res Perspect"},{"key":"8596_CR50","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10792-015-0124-0","volume":"35","author":"TS Fidelix de","year":"2015","unstructured":"de Fidelix TS, Vieira LA, de Freitas D, Trevisani VF (2015) Biologic therapy for refractory scleritis: a new treatment perspective. Int Ophthalmol 35:903\u2013912","journal-title":"Int Ophthalmol"},{"key":"8596_CR51","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275\u20132285 Erratum in: JAMA. 2006 Jun 7;295(21):2482","journal-title":"JAMA"},{"key":"8596_CR52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","volume":"76","author":"JM Berthelot","year":"2009","unstructured":"Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Liot\u00e9 F, Goeb V et al (2009) Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76:28\u201334","journal-title":"Joint Bone Spine"},{"key":"8596_CR53","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/art.22027","volume":"54","author":"JE Salmon","year":"2006","unstructured":"Salmon JE, Alpert D (2006) Are we coming to terms with tumor necrosis factor inhibition in pregnancy? Arthritis Rheum 54:2353\u20132355","journal-title":"Arthritis Rheum"},{"key":"8596_CR54","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/rheumatology\/kem068","volume":"46","author":"I Rosner","year":"2007","unstructured":"Rosner I, Haddad A, Boulman N, Feld J, Avshovich N, Slobodin G et al (2007) Pregnancy in rheumatology patients exposed to anti-tumor [TNF]-alpha therapy. Rheumatology 46:1508\u20131509","journal-title":"Rheumatology"},{"key":"8596_CR55","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0960327114550882","volume":"34","author":"S Mozaffari","year":"2015","unstructured":"Mozaffari S, Abdolghaffari AH, Nikfar S, Abdollahi M (2015) Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Hum Exp Toxicol 34:445\u2013459","journal-title":"Hum Exp Toxicol"},{"key":"8596_CR56","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1016\/S0002-9270(02)05276-0","volume":"97","author":"LHB Bank","year":"2002","unstructured":"Bank LHB (2002) Unexpected dramatic clinical response of psoriasis lesions and unexpected pregnancy in an infertile patient in response to treatment with anti-tumor necrosis factor monoclonal antibody for Crohn\u2019s disease. Am J Gastroenterol 97:S260","journal-title":"Am J Gastroenterol"},{"key":"8596_CR57","doi-asserted-by":"crossref","first-page":"iii28","DOI":"10.1093\/rheumatology\/ken168","volume":"47","author":"M Ostensen","year":"2008","unstructured":"Ostensen M, Lockshin M, Doria A, Valesini G, Meroni PL, Gordon C et al (2008) Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology 47:iii28\u2013iii31","journal-title":"Rheumatology"},{"key":"8596_CR58","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140189","author":"ME Clowse","year":"2015","unstructured":"Clowse ME, Wolf DC, F\u00f6rger F, Cush FJ, Go A, Shaughnessy L (2015) Pregnancy outcomes in subjects exposed to certolizumab pegol. J Rheumatol. doi: 10.3899\/jrheum.140189","journal-title":"J Rheumatol"},{"key":"8596_CR59","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","volume":"22","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22:847\u2013861","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"8596_CR60","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.12659\/MSM.890270","volume":"20","author":"B Kolarz","year":"2014","unstructured":"Kolarz B, Madjan M, Darmochwal-Kolarz DA, Dryglewska M (2014) Antihpospholipid antibodies during 6-months treatment with infliximab: a preliminary report. Med Sci Mionit 20:1227\u20131231","journal-title":"Med Sci Mionit"},{"key":"8596_CR61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1600-0897.2008.00669.x","volume":"61","author":"EE Winger","year":"2009","unstructured":"Winger EE, Reed JL, Ashoush S, Ahuja El-Toukhy T, Taranisi M (2009) Treatment with adalimumab [HumiraR] and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol 61:113\u2013120","journal-title":"Am J Reprod Immunol"},{"key":"8596_CR62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0897.2008.00585.x","volume":"60","author":"EE Winger","year":"2008","unstructured":"Winger EE, Reed JL (2008) Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurent spontaneous abortion. Am J Reprod Immunol 60:8\u201316","journal-title":"Am J Reprod Immunol"},{"key":"8596_CR63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40265-013-0009-3","volume":"73","author":"ED Deeks","year":"2013","unstructured":"Deeks ED (2013) Certolizumab pegol. Review of its use in the rheumatoid arthritis treatment. Drugs 73:75\u201397","journal-title":"Drugs"},{"key":"8596_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-0378(97)00068-5","volume":"37","author":"NE Simister","year":"1997","unstructured":"Simister NE, Story CM (1997) Human placental Fc receptors and the transmission of antibodies from mother to fetus. J Reprod Immunol 37:1\u201323","journal-title":"J Reprod Immunol"},{"key":"8596_CR65","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13023-015-0332-8","volume":"10","author":"C Leroy","year":"2015","unstructured":"Leroy C, Rigot JM, Leroy M, Decanter C, Le Mapihan K, Parent AS et al (2015) Immunosuppressive drugs and fertility. Orphan J Rare Dis 10:136. doi: 10.1186\/s13023-015-0332-8","journal-title":"Orphan J Rare Dis"},{"key":"8596_CR66","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/rheumatology\/keu007","volume":"53","author":"M Micu","year":"2014","unstructured":"Micu M, Micu R, Surd S, Girlovanu M, Bolboaca S, Ostensen M (2014) TNF-\u03b1 inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. Rheumatology 53:1250\u20131255","journal-title":"Rheumatology"},{"key":"8596_CR67","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/art.38919","volume":"67","author":"M Wallenius","year":"2015","unstructured":"Wallenius M, Lie E, Daltveit AK, Salvesen KA, Skomsvoll JF, Kasltad S et al (2015) No excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs. Arthritis Rheum 67:296\u2013301","journal-title":"Arthritis Rheum"},{"key":"8596_CR68","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MIB.0000000000000596","volume":"22","author":"RA McConell","year":"2016","unstructured":"McConell RA, Mahadevan U (2016) Use of immunomodulators and biologics before, during and after pregnancy. Inflamm Bowel Dis 22:213\u2013223","journal-title":"Inflamm Bowel Dis"},{"key":"8596_CR69","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/acr.22516","volume":"67","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Cush J, Ahmed M, Bermas BL, Chakravarty E, Chambers C et al (2015) Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and systemic inflammatory diseases. Arthritis Care Res 67:313\u2013325","journal-title":"Arthritis Care Res"},{"key":"8596_CR70","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.autrev.2014.12.011","volume":"14","author":"M \u00d8stensen","year":"2015","unstructured":"\u00d8stensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse ME et al (2015) State of the art: reproduction and pregnancy in rheumatic diseases. Autoimmun Rev 14:376\u2013386","journal-title":"Autoimmun Rev"},{"key":"8596_CR71","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/OGX.0b013e31828aca19","volume":"68","author":"J Alijotas-Reig","year":"2013","unstructured":"Alijotas-Reig J, Garrido-Gimenez C (2013) Current concepts and new trends in the diagnosis and management of recurrent miscarriage. Obstet Gynecol Surv 68:445\u2013466","journal-title":"Obstet Gynecol Surv"},{"key":"8596_CR72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.fertnstert.2012.09.023","volume":"99","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2013","unstructured":"Practice Committee of the American Society for Reproductive Medicine (2013) Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril 99:63\u201368","journal-title":"Fertil Steril"},{"key":"8596_CR73","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(06)69204-0","volume":"368","author":"R Rai","year":"2006","unstructured":"Rai R, Regan L (2006) Recurrent miscarriage. Lancet 368:601\u2013611","journal-title":"Lancet"},{"issue":"5","key":"8596_CR74","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjh.12813","volume":"165","author":"IA Greer","year":"2014","unstructured":"Greer IA, Brenner B, Gris JC (2014) Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine? Br J Haematol 165(5):585\u2013599","journal-title":"Br J Haematol"},{"key":"8596_CR75","doi-asserted-by":"crossref","first-page":"28418","DOI":"10.3390\/ijms161226104","volume":"16","author":"LE Simcox","year":"2015","unstructured":"Simcox LE, Ormesher L, Tower C, Greer IA (2015) Thrombophilia and pregnancy complications. Int J Mol Sci 16:28418\u201328428","journal-title":"Int J Mol Sci"},{"key":"8596_CR76","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jri.2009.12.006","volume":"85","author":"B Toth","year":"2010","unstructured":"Toth B, Jeschke U, Rogenhofer N, Scholz C, W\u00fcrfel W, Thaler CJ (2010) Makrigiannakis a recurrent miscarriage: current concepts in diagnosis and treatment. J Reprod Imunol 85:25\u201332","journal-title":"J Reprod Imunol"},{"key":"8596_CR77","doi-asserted-by":"crossref","unstructured":"Rand JH (2007) The antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 136-4","DOI":"10.1182\/asheducation-2007.1.136"},{"key":"8596_CR78","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4:295\u2013306","journal-title":"J Thromb Haemost"},{"key":"8596_CR79","doi-asserted-by":"publisher","unstructured":"Levy RA, Dos Santos FC, de Jes\u00fas GR, de Jes\u00fas NR (2015) Antiphospholipid antibodies and antiphospholipid syndrome during pregnancy: diagnostic concepts. Front Immunol 6:205. doi: 10.3389\/fimmu.2015.00205 . eCollection","DOI":"10.3389\/fimmu.2015.00205"},{"key":"8596_CR80","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rce.2015.09.003","volume":"216","author":"E Esteve-Valverde","year":"2016","unstructured":"Esteve-Valverde E, Ferrer-Oliveras R, Alijotas-Reig J (2016) Obstetric antiphospholipid syndrome. Rev Clin Esp 216:135\u2013145","journal-title":"Rev Clin Esp"},{"key":"8596_CR81","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/BOR.0000000000000200","volume":"27","author":"CB Chighizola","year":"2015","unstructured":"Chighizola CB, Raschi E, Borghi MO, Meroni PL (2015) Update on the pathogenesis and treatment of the antiphospholipid syndrome. Curr Opin Rheumatol 27:476\u2013482","journal-title":"Curr Opin Rheumatol"},{"key":"8596_CR82","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1177\/0961203312440058","volume":"21","author":"J Alijotas-Reig","year":"2012","unstructured":"Alijotas-Reig J, Ferrer-Oliveras R, EUROAPS Study Group (2012) The European registry on obstetric antiphospholipid syndrome (EUROAPS): a preliminary first year report. Lupus 21:766\u2013768","journal-title":"Lupus"},{"key":"8596_CR83","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000369363","volume":"24","author":"FY Azizieh","year":"2015","unstructured":"Azizieh FY, Raghupathy RG (2015) Tumor necrosis factor-\u03b1 and pregnancy complications: a prospective study. Med Princ Pract 24:165\u2013170","journal-title":"Med Princ Pract"},{"key":"8596_CR84","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1600-0897.2010.00946.x","volume":"65","author":"EE Winger","year":"2011","unstructured":"Winger EE, Reed JL, Ashoush S, El-Toukhy T, Ahuja S, Taranisi M (2011a) Degree of THF-\u03b1\/IL-10 cytokine elevation correlates with IVF success rates in women undergoing treatment with adalimumab (Humira) and IVIG. Am J Reprod Immunol 65:610\u2013618","journal-title":"Am J Reprod Immunol"},{"key":"8596_CR85","first-page":"214","volume":"66","author":"EE Winger","year":"2011","unstructured":"Winger EE, Reed JL, Ashoush S, El-Toukhy T, Ahuja S, Taraanisi M (2011b) Birth defect rates in women using adalimumab (Humira) to treat immunologic-based infertility in IVF patients. Am J Repord Immunol 66:214\u2013223","journal-title":"Am J Repord Immunol"},{"key":"8596_CR86","unstructured":"Alijotas-Reig J, Steve-Valverde E, Ferrer-Oliveras R, Llurba E, Mekinian A (in press) Treatment of refractory poor aPL-related obstetric outcomes with anti-TNF blockers: maternal-foetal outcomes in a series of 11 cases. J Autoimmun"},{"key":"8596_CR87","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000368605","volume":"37","author":"E Llurba","year":"2015","unstructured":"Llurba E, Crispi F, Verlohren S (2015) Update on the pathophysiological implications and clinical role of angiogenic factors in pregnancy. Fetal Diagn Ther 37:81\u201392","journal-title":"Fetal Diagn Ther"},{"key":"8596_CR88","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/10641955.2015.1032054","volume":"34","author":"A Harmon","year":"2015","unstructured":"Harmon A, Cornelius D, Maral L, Paige A, Herse F, Ibrahim T et al (2015) IL-10 supplementation increase Tregs and decreases hypertension in the RUPP rat model of preeclampsia. Hypertens Pregnancy 34:291\u2013306","journal-title":"Hypertens Pregnancy"},{"key":"8596_CR89","doi-asserted-by":"publisher","first-page":"219","DOI":"10.11604\/pamj.205.20.219.5317","volume":"20","author":"I Udenze","year":"2015","unstructured":"Udenze I, Amadi C, Awolola N, Makwe C (2015) The role of cytokines as inflammatory mediators in preeclampsia. Pan Afr Med J 20:219. doi: 10.11604\/pamj.205.20.219.5317 eCollection 2015","journal-title":"Pan Afr Med J"},{"key":"8596_CR90","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.mam.2007.02.006","volume":"28","author":"S Saito","year":"2007","unstructured":"Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y (2007) The role of the immune system in pre-eclampsia. Mol Asp Med 28:192\u2013209","journal-title":"Mol Asp Med"},{"key":"8596_CR91","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0165-0378(03)00052-4","volume":"59","author":"SA Robertson","year":"2003","unstructured":"Robertson SA, Bromfield JJ, Tremellen KP (2003) Seminal \u2018priming\u2019 for protection from pre-eclampsia-a unifying hypothesis. J Reprod Immunol 59:253\u2013265","journal-title":"J Reprod Immunol"},{"key":"8596_CR92","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/HYPERTENSIONAHA.110.163329","volume":"57","author":"Z Lai","year":"2011","unstructured":"Lai Z, Kalkunte S, Sharma S (2011) A critical role of interleukin-10 in modulating hypoxia-induced preeclampsia-like disease in mice. Hypertension 57:505\u2013514","journal-title":"Hypertension"},{"key":"8596_CR93","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/187152510792481234","volume":"8","author":"OM Reslan","year":"2010","unstructured":"Reslan OM, Khalil RA (2010) Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia. Cardiovasc Hematol Agents Med Chem 8:204\u2013226","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"8596_CR94","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5144\/0256-4947.2000.4","volume":"20","author":"SO Olusi","year":"2000","unstructured":"Olusi SO, Diejomaoh M, Omu A, Abdulaziz A, Prabha K, George S (2000) Interleukins in preeclampsia. Annals of Saudi Medicine 20:4\u20138","journal-title":"Annals of Saudi Medicine"},{"key":"8596_CR95","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2393-5-14","volume":"5","author":"JT Afshar","year":"2005","unstructured":"Afshar JT, Ghomian N, Shameli A, Shakeri M, Fahmidehkar MA, Mahajer E (2005) Determination of interleukin-6 and tumor necrosis factor-alpha concentrations in Iranian-Khorasanian patients with preeclampsia. BMC Pregnancy and Childbirth 5:14","journal-title":"BMC Pregnancy and Childbirth"},{"key":"8596_CR96","first-page":"937","volume":"84","author":"IA Greer","year":"1994","unstructured":"Greer IA, Lyall F, Perera T, Boswell F, Macara LM (1994) Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? Obstet Gynaecol 84:937\u2013940","journal-title":"Obstet Gynaecol"},{"key":"8596_CR97","doi-asserted-by":"publisher","first-page":"e0157584","DOI":"10.1371\/journal.pone.0157584","volume":"11","author":"IC Weel","year":"2016","unstructured":"Weel IC, Baergen RN, Rom\u00e3o-Veiga M, Borges VT, Ribeiro VR, Witkin SS et al (2016) Association between placental lesions, cytokines and angiogenic factors in pregnant women with preeclampsia. PLoS One 11:e0157584. doi: 10.1371\/journal.pone.0157584 eCollection 2016","journal-title":"PLoS One"},{"key":"8596_CR98","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jri.2015.02.007","volume":"109","author":"MF Gomaa","year":"2015","unstructured":"Gomaa MF, Naguib AH, Swedan KH, Abdellatif SS (2015) Serum tumor necrosis factor-\u03b1 level and uterine artery Doppler indices at 11-13\u00a0weeks\u2019 gestation for preeclampsia screening in low-risk pregnancies: a prospective observational study. J Reprod Immunol 109:31\u201334","journal-title":"J Reprod Immunol"},{"key":"8596_CR99","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3109\/14767058.2015.1022865","volume":"29","author":"SB E Holanda-Moura","year":"2016","unstructured":"E Holanda-Moura SB, Park F, Murthi P, Martins WP, Kane SC, Williams P et al (2016) TNF-R1 as a first trimester marker for prediction of pre-eclampsia. J Matern Fetal Neonatal Med 29:897\u2013903","journal-title":"J Matern Fetal Neonatal Med"},{"key":"8596_CR100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.placenta.2010.12.005","volume":"32","author":"B Xu","year":"2011","unstructured":"Xu B, Nakhla S, Makris A, Hennessy A (2011) TNF-\u03b1 inhibits trophoblast integration into endothelial cellular networks. Placenta 32:241\u2013246","journal-title":"Placenta"},{"key":"8596_CR101","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3109\/14767058.2015.1057811","volume":"29","author":"MI Vargas-Rojas","year":"2016","unstructured":"Vargas-Rojas MI, Solleiro-Villavicencio H, Soto-Vega E (2016) Th1, Th2, Th17 and Treg levels in umbilical cord blood in preeclampsia. J Matern Fetal Neonatal Med 29:1642\u20131645","journal-title":"J Matern Fetal Neonatal Med"},{"key":"8596_CR102","first-page":"334","volume":"6","author":"S Savaj","year":"2012","unstructured":"Savaj S, Vaziri D (2012) An overview of recent advances in pathogenesis and diagnosis of preeclampsia. Kidney Dis 6:334\u2013338","journal-title":"Kidney Dis"},{"key":"8596_CR103","unstructured":"Karumanchi SA (2016) Angiogenic factors in preeclampsia from diagnosis to therapy. Hypertension 67"},{"key":"8596_CR104","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14728214.2015.1062875","volume":"20","author":"JM Sasser","year":"2015","unstructured":"Sasser JM, Murphy SR, Granger JP (2015) Emerging drugs for preeclampsia\u2014the endothelium as a target. Exp Opin Emerg Drugs 20:527\u2013530","journal-title":"Exp Opin Emerg Drugs"},{"key":"8596_CR105","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/aji.12493","volume":"76","author":"A Mekinian","year":"2016","unstructured":"Mekinian A, Cohen J, Alijotas-Reig J, Carbillon L, Nicaise-Roland P, Kayem G et al (2016) Unexplained recurrent miscarriage and recurrent implantation failure: is there a place for immunomodulation? Am J Reprod Immunol 76:8\u201328","journal-title":"Am J Reprod Immunol"},{"key":"8596_CR106","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cyto.2016.02.014","volume":"81","author":"B Hu","year":"2016","unstructured":"Hu B, Yang J, Huang Q, Bao J, Brennecke SP, Liu H (2016) Cyclosporin a significantly improves preeclampsia signs and suppresses inflammation in a rat model. Cytokine 81:77\u201381","journal-title":"Cytokine"},{"key":"8596_CR107","first-page":"1888041","volume":"8","author":"L Qian","year":"2015","unstructured":"Qian L, Wang H, Wu F, Li M, Chen W, Lianzheng LV (2015) Vitamin D3 alters Toll-like receptor 4 signaling in monocytes of pregnant women at risk for preeclampsia. Int J Clin Exp Med 8:1888041\u20131888049","journal-title":"Int J Clin Exp Med"},{"key":"8596_CR108","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1152\/ajpregu.00069.2012","volume":"304","author":"SR Murphy","year":"2013","unstructured":"Murphy SR, LaMarca BB, Parrish M, Cockrell K, Granger JP (2013) Control of soluble fms-like tyrosine-1 (sFlt-1) production response to placental ischemia\/hypoxia: role of tumor necrosis factor-\u03b1. Am J Physiol Regul Integr Comp Physiol 304:R130\u2013R135","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"8596_CR109","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/HJH.0b013e3283468392","volume":"29","author":"J Gutkowska","year":"2011","unstructured":"Gutkowska J, Granger JP, Lamarca BB, Danalache BA, Wang D, Jankowski M (2011) Changes in cardiac structure in hypertension produced by placental ischemia in pregnant rats: effect of tumor necrosis factor blockade. J Hypertens 29:1203\u20131212","journal-title":"J Hypertens"},{"key":"8596_CR110","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2010.140822","volume":"70","author":"SM Verstappen","year":"2011","unstructured":"Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich K, BSRBR control centre consortium, BSR biologics Register (2011) Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:823\u2013826","journal-title":"Ann Rheum Dis"},{"key":"8596_CR111","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1741-7015-11-174","volume":"11","author":"OH Nielsen","year":"2013","unstructured":"Nielsen OH, Loftus EV, Jess T (2013) Safety of TNF-\u03b1 inhibitors during IBD pregnancy: a systematic review. BMC Med 11:174\u2013179","journal-title":"BMC Med"},{"key":"8596_CR112","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/art.38262","volume":"66","author":"WO Cooper","year":"2014","unstructured":"Cooper WO, Cheetham TC, De-Kun L, Stein M, Callahan ST, Morgan TM et al (2014) Adverse foetal outcomes associated with immunosuppressive medications for chronic immune mediated diseases in pregnancy. Arthritis Rheumatol 66:444\u2013450","journal-title":"Arthritis Rheumatol"},{"key":"8596_CR113","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","volume":"43","author":"O Diav-Citrin","year":"2014","unstructured":"Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A (2014) Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol 43:78\u201384","journal-title":"Reprod Toxicol"},{"issue":"suppl 5","key":"8596_CR114","first-page":"14","volume":"8","author":"U Mahadevan","year":"2012","unstructured":"Mahadevan U, Martin CF, Sandler RS, Kane SV, Dubinsky M, Lewis JD (2012) PIANO: a 1,000-patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterol Hepatol 8(suppl 5):14\u201315","journal-title":"Gastroenterol Hepatol"},{"key":"8596_CR115","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/rheumatology\/ket409","volume":"53","author":"KL Hyrich","year":"2014","unstructured":"Hyrich KL, Verstappen SM (2014) Biologic therapies and pregnancy: the story so far. Rheumatology 53:1377\u20131385","journal-title":"Rheumatology"},{"key":"8596_CR116","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/1744666X.2016.1184973","volume":"12","author":"F F\u00f6rger","year":"2016","unstructured":"F\u00f6rger F, Villiger PM (2016) Treatment of rheumatoid arthritis during pregnancy: present and future. Expert Rev Clin Immunol 12:937\u2013944","journal-title":"Expert Rev Clin Immunol"},{"key":"8596_CR117","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.toxlet.2003.12.030","volume":"149","author":"R Cimaz","year":"2004","unstructured":"Cimaz R, Meregalli E, Biggioggero M, Borghi A, Tincani M, Motta M et al (2004) Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy. Toxicil Lett 149:155\u2013162","journal-title":"Toxicil Lett"},{"key":"8596_CR118","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13142","author":"K Sands","year":"2015","unstructured":"Sands K, Jansen R, Zaslau S, Greenwald D (2015) The safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment Pharmacol Ther. doi: 10.1111\/apt.13142","journal-title":"Aliment Pharmacol Ther"},{"key":"8596_CR119","unstructured":"European Medicines Agencie (2015) CIMZIA (certulizumab pegol) EMA summary of product characteristics. Available from : www.emea.europa.eu\/docs\/en_GB\/docuement_library\/EPAR__Product_Information\/human\/001037\/WC500069763.pdf . (Accesed 22 Sep 2015)."},{"key":"8596_CR120","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1136\/ard.2009.127423","volume":"69","author":"PM Villiger","year":"2010","unstructured":"Villiger PM, Caliezi G, Cottin V, Senn A, \u00d8stensen M (2010) Effects of TNF antagonists on sperm characteristics in patients with spondiloarthritis. Ann Rheum Dis 69:1842\u20131844","journal-title":"Ann Rheum Dis"},{"key":"8596_CR121","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2125.1992.tb04077.x","volume":"33","author":"EJ Begg","year":"1992","unstructured":"Begg EJ, Atkitson HC, Duffull SB (1992) Prospective evaluation of a model for the prediction of milk: plasma drug concentration from physicochemical characteristics. Br J Pharmacol 33:501\u2013505","journal-title":"Br J Pharmacol"},{"key":"8596_CR122","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MCG.0b013e31817f9367","volume":"43","author":"S Kane","year":"2009","unstructured":"Kane S, Ford J, Cohen R, Wagner C (2009) Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn\u2019s disease before and after delivery. J Clin Gastroenterol 43:613\u2013616","journal-title":"J Clin Gastroenterol"},{"key":"8596_CR123","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.crohns.2011.05.006","volume":"5","author":"S Ben-Horin","year":"2011","unstructured":"Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakin R et al (2011) Detection of infliximab in Brest milk or nursing mothers with inflammatory bowel disease. J Crohns Cloitis 5:555\u2013558","journal-title":"J Crohns Cloitis"},{"key":"8596_CR124","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3899\/jrheum.100077","volume":"37","author":"S Keeling","year":"2010","unstructured":"Keeling S, Wolbink GJ (2010) Measuring multiple etanercept levels in the breast milk of a nursing mother with rheumatoid arthritis [letter]. J Rheumatol 37:1551","journal-title":"J Rheumatol"},{"key":"8596_CR125","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/rheumatology\/keq185","volume":"49","author":"BG Berthelsen","year":"2010","unstructured":"Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT, Hellmuth E (2010) Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology 49:2225\u20132227","journal-title":"Rheumatology"},{"key":"8596_CR126","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cgh.2009.11.023","volume":"8","author":"S Ben-Horin","year":"2010","unstructured":"Ben-Horin S, Yavzori M, Katz L, Picard O, Fudim E, Chowers Y et al (2010) Adalimumab levels in breast milk of a nursing mother. Clin Gastroenterol Hepatol 8:475\u2013476","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8596_CR127","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ajog.2014.05.040","volume":"211","author":"CS Broussard","year":"2014","unstructured":"Broussard CS, Frey MT, Hernandez-Diaz S, Green MF, Chambers CD, Sahin L et al (2014) Developing a systematic approach to safer medication use during pregnancy: summary of a centers for disease control and prevention-convened meeting. Am J Obstet Gynecol 211:208\u2013214","journal-title":"Am J Obstet Gynecol"},{"key":"8596_CR128","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","volume":"36","author":"JJ O\u2019Shea","year":"2012","unstructured":"O\u2019Shea JJ, Plenge R (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36:542\u2013550","journal-title":"Immunity"},{"key":"8596_CR129","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.molimm.2004.04.014","volume":"41","author":"JJ O\u2019Shea","year":"2004","unstructured":"O\u2019Shea JJ, Husa M, Li D, Hofmann SR, Watford W, Roberts JL et al (2004) Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol 41:727\u2013737","journal-title":"Mol Immunol"},{"key":"8596_CR130","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","volume":"270","author":"SM Russell","year":"1995","unstructured":"Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ et al (1995) Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270:797\u2013800","journal-title":"Science"},{"key":"8596_CR131","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.coph.2012.06.008","volume":"12","author":"A Kontzias","year":"2012","unstructured":"Kontzias A, Kotlyar A, Laurence A, Changelian P, O\u2019Shea JJ (2012) Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 12:464\u2013470","journal-title":"Curr Opin Pharmacol"},{"key":"8596_CR132","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clim.2012.09.009","volume":"148","author":"A Markopoulou","year":"2013","unstructured":"Markopoulou A, Kyttaris VC (2013) Small molecules in the treatment of systemic lupus erythematosus. Clin Immunol 148:359\u2013368","journal-title":"Clin Immunol"},{"key":"8596_CR133","doi-asserted-by":"publisher","DOI":"10.1002\/art.39818","author":"Y Furumoto","year":"2016","unstructured":"Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG et al (2016) Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis Rheumatol. doi: 10.1002\/art.39818","journal-title":"Arthritis Rheumatol"},{"key":"8596_CR134","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10875-015-0203-z","volume":"35","author":"S Yokoyama","year":"2015","unstructured":"Yokoyama S, Perera PY, Terawaki S, Watanabe N, Kaminuma O, Waldmann TA et al (2015) Janus kinase inhibitor tofacitinib shows potent efficacy in a mouse model of autoimmune lymphoproliferative syndrome (ALPS). J Clin Immunol 35:661\u2013667","journal-title":"J Clin Immunol"},{"key":"8596_CR135","first-page":"13","volume":"13","author":"S Miscia","year":"2002","unstructured":"Miscia S, Marchisio M, Grilli A, Di Valerio V, Centurione L, Sabatino G (2002) Tumor necrosis factor alpha (TNF-alpha) activates Jak1\/Stat3-Stat5B signaling through TNFR-1 in human B cells. Cell Growth Differ 13:13\u201318","journal-title":"Cell Growth Differ"},{"key":"8596_CR136","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.molimm.2005.10.008","volume":"43","author":"DD Taylor","year":"2006","unstructured":"Taylor DD, Bohler HC, Gercel-Taylor C (2006) Pregnancy-linked suppression of TcR signaling pathways by a circulating factor absent in recurrent spontaneous pregnancy loss. Mol Immunol 43:1872\u20131880","journal-title":"Mol Immunol"},{"key":"8596_CR137","doi-asserted-by":"crossref","unstructured":"von Versen-H\u00f6ynck FI, Rajakumar A, Parrott MS, Powera RW (2009) Leptin affects system A amino acid transport activity in the human placenta: evidence for STAT3 dependent mechanisms. Placenta 30:361\u2013367","DOI":"10.1016\/j.placenta.2009.01.004"},{"key":"8596_CR138","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00644.x","volume":"223","author":"M Pesu","year":"2008","unstructured":"Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O\u2019Shea JJ (2008) Therapeutic targeting of Janus kinases. Immunolo Rev 223:132\u2013142","journal-title":"Immunolo Rev"},{"key":"8596_CR139","unstructured":"Henriques C (2016) AbbVie launches phase 3 trial for rheumatoid arthritis. Rheumatoid Arthritis News. BioNews Services, LLC. Retrieved 16 July 2016"},{"key":"8596_CR140","doi-asserted-by":"crossref","first-page":"e0163252","DOI":"10.1371\/journal.pone.0163252","volume":"11","author":"J Cai","year":"2016","unstructured":"Cai J, Li M, Huang Q, Fu X, Wu H (2016) Differences in cytokine expression and STAT3 activation between healthy controls and patients of unexplained recurrent spontaneous abortion (URSA) during early pregnancy. PLoS One 11:e0163252","journal-title":"PLoS One"},{"key":"8596_CR141","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5830\/CVJA-2016-009","volume":"27","author":"P Gathiram","year":"2016","unstructured":"Gathiram P, Moodley J (2016) Pre-eclampsia: its pathogenesis and pathophysiology. Cardiovasc J Afr 27:71\u201378","journal-title":"Cardiovasc J Afr"},{"key":"8596_CR142","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.3760\/cma.j.issn.0366-6999.20140290","volume":"127","author":"Z Liang","year":"2014","unstructured":"Liang Z, Zhu J, Wang Y, Wang Y, Zhang Y, Lin J, Di W (2014) Three transcription factors and the way immune cells affected by different plasma change in opposite ways in the development of the syndrome of pre-eclampsia. Chin Med J 127:2252\u20132258","journal-title":"Chin Med J"},{"key":"8596_CR143","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.preghy.2012.04.292","volume":"2","author":"DG Ferreira","year":"2012","unstructured":"Ferreira DG, Cavalhieri LT, Ventura AC, Aires FT, Garcia JM, Mesquita MR et al (2012l) The role of the JAK-STAT pathways and SOCS in preeclampsia. Pregnancy Hypertens 2:338\u2013339","journal-title":"Pregnancy Hypertens"},{"key":"8596_CR144","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/aji.12329","volume":"73","author":"SB Cheng","year":"2015","unstructured":"Cheng SB, Sharma S (2015) Interleukin-10: a pleiotropic regulator in pregnancy. Am J Reoprod Immunol 73:487\u2013500","journal-title":"Am J Reoprod Immunol"},{"key":"8596_CR145","first-page":"926875","volume":"2014","author":"N Yin","year":"2014","unstructured":"Yin N, Zhang H, Luo X, Ding Y, Xiao X, Liu X et al (2014) IL-27 activates human trophoblasts to express IP-10 and IL-6: implications in the immunopathophysiology of preeclampsia. Mediat Inflamm 2014:926875","journal-title":"Mediat Inflamm"},{"key":"8596_CR146","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0897.2011.01075.x","volume":"67","author":"GD Eastabrook","year":"2012","unstructured":"Eastabrook GD, Hu Y, Tan R, Dutz JP, Maccalman CD, von Dadelszen P (2012) Decidual NK cell-derived conditioned medium (dNK-CM) mediates VEGF-C secretion in extravillous cytotrophoblasts. Am J Reprod Immunol 67:101\u2013111","journal-title":"Am J Reprod Immunol"},{"key":"8596_CR147","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1084\/jem.194.2.189","volume":"194","author":"M Ernst","year":"2001","unstructured":"Ernst M, Inglese M, Waring P, Campbell IK, Bao S, Caly FJ (2001) Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J Exp Med 194:189\u2013203","journal-title":"J Exp Med"},{"key":"8596_CR148","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.febslet.2006.04.029","volume":"580","author":"H Nakamura","year":"2006","unstructured":"Nakamura H, Kimura T, Koyama S, Ogita K, Tsutsui T, Shimoya T et al (2006) Mouse model of human infertility: transient and local inhibition of endometrial STAT-3 activation results in implantation failure. FEBS Lett 580:2717\u20132722","journal-title":"FEBS Lett"},{"key":"8596_CR149","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1095\/biolprepod.112.100016","volume":"87","author":"AJH Albaghdadi","year":"2012","unstructured":"Albaghdadi AJH, Kan FWK (2012) Endometrial receptivity defects and impaired implantation in diabetic NOD mice. Biol Reprod 87:30. doi: 10.1095\/biolprepod.112.100016","journal-title":"Biol Reprod"},{"key":"8596_CR150","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/me.2013-1086","volume":"27","author":"X Sun","year":"2013","unstructured":"Sun X, Bartos A, Whitsett JA, Dey SK (2013) Uterine deletion of gp130 or STAST3 shows implantation failure with increased estrogenic responses. Mol Endocrinol 27:1492\u20131501","journal-title":"Mol Endocrinol"},{"key":"8596_CR151","doi-asserted-by":"crossref","first-page":"e0157696","DOI":"10.1371\/journal.pone.0157696","volume":"11","author":"Y Choi","year":"2016","unstructured":"Choi Y, Kim HR, Lim EJ, Park M, Yoon JA, Kim YS et al (2016) Integrative analyses of uterine transcriptome and MicroRNAome reveal compromised LIF-STAT3 signaling and progesterone response in the endometrium of patients with recurrent\/repeated implantation failure (RIF). PLoS One 11:e0157696","journal-title":"PLoS One"},{"key":"8596_CR152","doi-asserted-by":"crossref","first-page":"e29660","DOI":"10.1371\/journal.pone.0029660","volume":"7","author":"S D\u2019Ippolito","year":"2012","unstructured":"D\u2019Ippolito S, Marana R, Di Nicuolo F, Castellani R, Veglia M, Stinson J et al (2012) Effect of low molecular weight heparins (LMWHs) on antiphospholipid antibodies (aPL)-mediated inhibition of endometrial angiogenesis. PLoS One 7:e29660","journal-title":"PLoS One"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-016-8596-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8596-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8596-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T11:06:50Z","timestamp":1718968010000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-016-8596-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,4]]},"references-count":152,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["8596"],"URL":"https:\/\/doi.org\/10.1007\/s12016-016-8596-x","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,4]]}}}